Dr. Katrina Winsnes
Claim this profileOregon Health and Science University
Expert in Cancer
Expert in Soft Tissue Sarcoma
26 reported clinical trials
46 drugs studied
About Katrina Winsnes
Education:
- Obtained MD (Doctor of Medicine) from Oregon Health and Science University (OHSU) in 2015.
- Completed Residency in Internal Medicine at OHSU in 2018.
- Finished Fellowship in Hematology and Medical Oncology at OHSU in 2021.
Experience:
- Currently serves as an Assistant Professor of Medicine at OHSU, with a specialization in Hematology and Medical Oncology.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Soft Tissue Sarcoma
Global LeaderStage I
Stage II
MTOR positive
Affiliated Hospitals
Clinical Trials Katrina Winsnes is currently running
DAY101
for Langerhans Cell Histiocytosis
This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting1 award Phase 228 criteria
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
More about Katrina Winsnes
Clinical Trial Related8 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Katrina Winsnes has experience with
- Cyclophosphamide
- Cisplatin
- Ramucirumab
- Larotrectinib
- Carboplatin
- Etoposide
Breakdown of trials Katrina Winsnes has run
Cancer
Soft Tissue Sarcoma
Wilms Tumor
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Katrina Winsnes specialize in?
Katrina Winsnes focuses on Cancer and Soft Tissue Sarcoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Katrina Winsnes currently recruiting for clinical trials?
Yes, Katrina Winsnes is currently recruiting for 7 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Katrina Winsnes has studied deeply?
Yes, Katrina Winsnes has studied treatments such as Cyclophosphamide, Cisplatin, Ramucirumab.
What is the best way to schedule an appointment with Katrina Winsnes?
Apply for one of the trials that Katrina Winsnes is conducting.
What is the office address of Katrina Winsnes?
The office of Katrina Winsnes is located at: Oregon Health and Science University, Portland, Oregon 97239 United States. This is the address for their practice at the Oregon Health and Science University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.